Scarica l'app Stockscreener
2.65
4.33%
-0.12
Dopo l'orario di chiusura:
2.62
-0.03
-1.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
EDIT: EDIT-401 targets up to 90% LDL reduction, with first patient dosing on track for this year - TradingView
Editas Medicine at Cantor conference: in vivo CRISPR push advances - Investing.com
Editas Medicine (NASDAQ: EDIT) Grants 950,000 Derivative Securities to CMO Ory Daniel Scott on September 8, 2026 - Kalkine Media
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Editas Medicine (NASDAQ: EDIT) awards options vesting through 2030 to its CMO - Stock Titan
Editas Medicine (NASDAQ: EDIT) CMO named as reporting insider - Stock Titan
Editas Medicine grants stock options to new chief medical officer - Investing.com
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Australia
New medical chief can earn the right to buy 950,000 Editas shares - Stock Titan
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - GlobeNewswire
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - MarketBeat
Editas Medicine, Inc. SEC Filing (Sep 9, 2026) - Stock Titan
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com South Africa
EDIT: EDIT-401 aims for unprecedented LDL reduction, with first human data expected in 2027 - TradingView
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR By Investing.com - Investing.com India
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com
Editas Medicine CFO Parison Amy Retains 13,839 Shares After Selling 453 at $3.04 Each - Kalkine Media
Editas Medicine Appoints Dan Ory as Chief Medical Officer - citybiz
A potential gene-editing treatment moves toward trials as Editas adds a veteran with more than 25 years' experience. - Stock Titan
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - Yahoo Finance
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media
Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - Kalkine Media
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat
Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan
Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn
EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Boston and New York will host Editas Medicine talks this month - Stock Titan
Editas Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Editas Medicine Files $400 Million Mixed Shelf - marketscreener.com
O'Neill plans another Editas (NASDAQ: EDIT) sale after June share trade - Stock Titan
Editas Medicine (EDIT) officer flags 700-share stock sale - Stock Titan
Editas Medicine stock holds steady as investors weigh latest gene editing progress - ad-hoc-news.de
Nantahala Capital Management LLC Acquires Shares of 852,700 Editas Medicine, Inc. $EDIT - MarketBeat
EDIT Price History for Editas Medicine Stock - barchart.com
Editas Medicine Inc. (EDIT) Peer Comparison – Compare with Others - Value Research
ADAR1 Capital Management LLC Buys New Stake in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Certain Stock Options of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 25-AUG-2026. - marketscreener.com
EDIT Should I Buy - Intellectia AI
EDIT Stock Price, Quote & Chart - ChartMill
ETFs Investing in Editas Medicine, Inc. Stocks - TradingView
Editas Medicine (NASDAQ:EDIT) Trading 14.4% HigherHere's What Happened - MarketBeat
Ladenburg Thalmann Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $6 - Moomoo
EDIT Initiates Coverage On Ladenburg ThalmannRating Set to Bu - GuruFocus
Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP - MarketBeat
EDIT Q2 2026 Earnings: Narrower-than-Expected Loss Underscores Cost DisciplineRevenue Growth Report - vinanet.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Editas Medicine Inc (EDIT) Stock Price, Trades & News - GuruFocus
Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership - Stock Titan
Editas Medicine (EDIT) Slides 3.7% as Gene-Editing Stock Tests Key Support at $2.70Collar Trade - vinanet.vn
Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT - MarketBeat
Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Editas Medicine (EDIT) Short Interest & Short Float | Updated Aug 2026 $EDIT - MarketBeat
Editas Medicine (EDIT) Slips to $2.81 as Gene-Editing Stock Nears Critical SupportSchiff Line - dars.gov.et
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):